Pipeline Insight: Cancer Overview- Breast and Gynecological Cancers - Promising agents emerge for BRCA positive patients

Typ der Studie:	Marktstudie
Jahrgang:	01/2011
Herausgeber:	Datamonitor
Sprachversion:	Englisch
Verfügbarkeit:	Lieferbar

Preis**
(Lieferformat):

11.400,00$ netto SlidePack

Versandkostenfrei

** WICHTIG:
Alle Preise sind netto ausgewiesen. Abhängig von Versand- und Leistungsort ist hierauf noch USt. zu entrichten (Deutschland z.Z. 19%).

Der korrekte Gesamtendpreis wird Ihnen mit der Angabe Ihrer Rechnungsadresse, USt-ID-Nr. etc. im Bestellverlauf ausgewiesen. Weitere Informationen zu den Bestandteilen des Kaufpreises finden Sie in unseren FAQs.

Zahlen und Fakten zur Studie:

266+28 seiten

Inhalt der Studie:

Mehr über diese Studie

Introduction
The three tumor types covered in this report are set to account for just over 585,000 new cancer cases in 2010 with forecasts of over 656,000 new cases in 2019. Collectively the drugs profiled in this report for breast and ovarian cancer are forecast to achieve almost $3.0 billion in sales in the seven major pharmaceutical markets in 2019.

Scope of this research
Examination of the breast and ovarian cancer pipelines with in-depth clinical and commercial profiles of Phase III candidates Seven major pharmaceutical market sales forecasts for Phase III pipeline products through to 2019 with product-specific assumptions Segmentation and analysis of the current breast and ovarian cancer pipelines by phase of development, drug class and company Insight and analysis of breast, ovarian and cervical cancer markets including commercial opportunity, epidemiology and discussion of unmet needs Research and analysis highlights
There are currently 94 drugs in clinical development for breast cancer, of which 8 are in late phase development (preregistration, Phase III or pivotal Phase II trial). Collectively, the drugs forecast in this report for breast cancer are forecast to achieve $1.1 billion in sales by 2019.

There are currently 41 drugs in the pipeline for ovarian cancer, of which 10 are in late-phase development. Collectively, the drugs in late-phase development for ovarian cancer profiled in this report are forecast to achieve $1.8bn in sales by 2019.

R&D interest in cervical cancer is limited compared with other cancers and as a result there is a lack of novel drug candidates in late-phase development. Despite poor outcomes and prognoses for late-stage patients, recent focus has been directed towards preventative strategies rather than treatment.

Key reasons to purchase this research
Identify key drugs within the breast and ovarian cancer pipelines based on sales forecasts and Datamonitor drug assessment Characterize unmet needs within breast, ovarian and cervical cancers and assess the potential for pipeline products to fulfill them Assess the shifting breast, ovarian and cervical cancer market dynamics and how future treatment will incorporate pipeline products
[Studien Infos ausblenden]

Inhaltsverzeichnis

Hinweis:

* Der Rechnungsbetrag für diese Studie wird in $ (Dollar) ausgewiesen. Kunden aus dem Inland bekommen von uns eine Rechnung in Euro, umgerechnet zum letztwöchigen Schlusskurs

Warenkorb

Pipeline Insight: Cancer Overview- Breast and Gynecological Cancers - Promising agents emerge for BRCA positive patients

Copyright 2012 by dynamic technologies GmbH

	Weitere Studien von Datamonitor: Treatment Algorithms: Type 2 Diabetes – Novel classes drive fragmentation of treatment choices in type 2 diabetes What Consumers Want: Checking Accounts in Canada 2011 Epidemiology: Bipolar Disorders – Population growth to mean more patients with bipolar disorders Male Grooming in India: Responses to Emerging Needs and Changing Behavior Product Insights: Dairy in the US [Mehr...]